SANION Saniona AB (publ)
Saniona AB (publ), a clinical-stage biopharmaceutical company, focuses on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders in Ireland, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy that has completed Phase 2 clinical trial for the treatment of hypothalamic obesity and Prader-Willi syndrome; ACP-711, a positive allosteric modulator of GABAA a3 containing receptors that has completed Phase 1 clinical trial for the treatment of essential tremor; SAN903, a novel medicine based on inhibition of the calcium-activated potassium ion channel, which has completed preclinical development for the treatment of inflammatory bowel disease; SAN2219, a subtype selective positive allosteric modulator of GABAA a2- a3- and a5 that is in preclinical stage for treatment of acute repetitive seizures; SAN2355 to treat resistant focal onset seizures; SAN2668, a therapy for severe pediatric epilepsies, including developmental epileptic encephalopathies; and SAN2465, a negative allosteric modulator to treat major depressive disorder. It has research and collaboration agreements with Boehringer Ingelheim International GmbH to research, develop, manufacture, and commercialize therapeutics; license agreement with Productos Medix, S.A. de C.V. develop and commercialize tesofensine and/or Tesomet; research services agreement and a collaboration agreement with Cephagenix ApS to identify and develop novel migraine treatments; and research collaboration with AstronauTx to research, develop, manufacture, and commercialize therapeutics for Alzheimer's disease. The company was founded in 2011 and is headquartered in Glostrup, Denmark.…
Industry Peers
BiotechnologyKey Statistics
About Saniona (STO: SANION)
›
Saniona (STO: SANION) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 44 employees.
The shares were at 11.23 SEK on 20 November 2026, down 24.7% over 52 weeks. Its 52-week range is 8.525 SEK to 28.30 SEK: the price is 60.3% below the high and 31.7% above the low.
At a market capitalisation of 1.55B SEK, it trades at 8.7 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 74% for SANION.
Saniona reports return on equity of 44.8%, an operating margin of 47.1% and revenue down 51.0% year over year.
It holds more cash than debt, a net cash position of 486.31M SEK. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 19.00 SEK is 69.2% above the current price.